
    
      This will be a controlled, randomised study, to be performed in 15-20 pancreas
      transplantation centers throughout Europe. Patients will be randomised into one of two
      treatment groups. Group 1 will receive Tacrolimus and Mycophenolate Mofetil (= best group in
      EuroSPK001 trial). Group 2 will receive Tacrolimus and Sirolimus. Both groups will receive in
      association short-term corticosteroids and polyclonal antibody preparation. Patients will be
      randomly assigned to one of the 2 treatment groups in a 1:1 ratio before transplantation. The
      study will last 3 years, with a first interim analysis of the data at 6 months and a complete
      analysis at 1 year.
    
  